[go: up one dir, main page]

MA27615A1 - Composes de pyrazolo[3,4-b]pyridine et leur utilisation en tant qu'inhibiteurs de phosphodiesterase - Google Patents

Composes de pyrazolo[3,4-b]pyridine et leur utilisation en tant qu'inhibiteurs de phosphodiesterase

Info

Publication number
MA27615A1
MA27615A1 MA28404A MA28404A MA27615A1 MA 27615 A1 MA27615 A1 MA 27615A1 MA 28404 A MA28404 A MA 28404A MA 28404 A MA28404 A MA 28404A MA 27615 A1 MA27615 A1 MA 27615A1
Authority
MA
Morocco
Prior art keywords
optionally substituted
alkyl
formula
represented
fluoroalkyl
Prior art date
Application number
MA28404A
Other languages
English (en)
Inventor
George Allen David
Mary Coe Diane
Mary Cook Caroline
William James Cooper Anthony
Dennis Dowle Michael
David Edlin Christopher
Nicole Hamblin Julie
Redpath Johnson Martin
Spencer Jones Paul
Kristian Lindvall Mika
Jane Mitchell Charlotte
Judith Redgrave Alison
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0230165A external-priority patent/GB0230165D0/en
Priority claimed from GB0307998A external-priority patent/GB0307998D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA27615A1 publication Critical patent/MA27615A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne un composé représenté par la formule (I) ou un de ses sels dans laquelle: R1 représente alkyle C1-4, fluoroalkyle C1-3 ou -(CH2)2OH; R2 représente un atome d'hydrogène (H), méthyle ou fluoroalkyle C1; R3a représente un atome d'hydrogène (H) ou alkyle C1-3; R3 représente alkyle C3-6 ramifié éventuellement substitué, cycloalkyle C3-8 éventuellement substitué, cycloalkényle C5-7 monoinsaturé éventuellement substitué, phényle éventuellement substitué ou un groupe hétérocyclique éventuellement substitué, représenté par la formule secondaire (aa), (bb) ou (cc) dans lesquelles n1 et n2 sont indépendamment 1 ou 2; et Y représente O, S, SO2, ou NR4; et dans laquelle Het est représenté par les formules secondaires (i), (ii), (iii), (iv) ou (v). Ces composés sont des inhibiteurs de phosphodiestérase (PDE), en particulier, des inhibiteurs de PDE4. Elle concerne également la mise en application d'un composé représenté par la formule (I) ou d'un de ses sels acceptables sur le plan pharmaceutique afin de préparer un médicament servant à traiter et/ou à prévenir une maladie inflammatoire et/ou allergique chez un mammifère, tel que l'humain, par exemple, la broncho-pneumopathie chronique obstructive, l'asthme ou la rhinite allergique.
MA28404A 2002-12-23 2005-07-20 Composes de pyrazolo[3,4-b]pyridine et leur utilisation en tant qu'inhibiteurs de phosphodiesterase MA27615A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0230045.7A GB0230045D0 (en) 2002-12-23 2002-12-23 Compounds
GB0230165A GB0230165D0 (en) 2002-12-24 2002-12-24 Compounds
GB0307998A GB0307998D0 (en) 2003-04-07 2003-04-07 Compounds

Publications (1)

Publication Number Publication Date
MA27615A1 true MA27615A1 (fr) 2005-11-01

Family

ID=32685762

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28404A MA27615A1 (fr) 2002-12-23 2005-07-20 Composes de pyrazolo[3,4-b]pyridine et leur utilisation en tant qu'inhibiteurs de phosphodiesterase

Country Status (28)

Country Link
US (1) US7528148B2 (fr)
EP (1) EP1581532B1 (fr)
JP (1) JP4872068B2 (fr)
KR (1) KR101088848B1 (fr)
CN (1) CN1751042B (fr)
AR (1) AR043683A1 (fr)
AT (1) ATE466012T1 (fr)
AU (2) AU2003293999B2 (fr)
BR (1) BR0317645A (fr)
CA (1) CA2511340C (fr)
CO (1) CO5690642A2 (fr)
CY (1) CY1110676T1 (fr)
DE (1) DE60332396D1 (fr)
DK (1) DK1581532T3 (fr)
ES (1) ES2345385T3 (fr)
GB (1) GB0230045D0 (fr)
IL (1) IL169335A0 (fr)
IS (1) IS2795B (fr)
MA (1) MA27615A1 (fr)
MX (1) MXPA05006923A (fr)
NO (1) NO332354B1 (fr)
NZ (2) NZ570085A (fr)
PL (2) PL377880A1 (fr)
PT (1) PT1581532E (fr)
SI (1) SI1581532T1 (fr)
TW (2) TWI354671B (fr)
WO (1) WO2004056823A1 (fr)
ZA (1) ZA200605901B (fr)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US20060089375A1 (en) * 2002-09-16 2006-04-27 Allen David G Pyrazolo[3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
AU2004299277A1 (en) * 2003-12-19 2005-06-30 Glaxo Group Limited Pyrazolo (3,4-b) pyridine compounds, and their use as phosphodiesterase inhibitors
GB0405933D0 (en) * 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds
EP1735314A1 (fr) * 2004-03-16 2006-12-27 Glaxo Group Limited Compose de pyrazolo [3,4-b]pyridine, et son utilisation en tant qu'inhibiteur de pdea4
WO2005118543A1 (fr) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. Inhibiteur des kinases et utilisation de cet inhibiteur
US7579335B2 (en) 2005-01-10 2009-08-25 Glaxo Group Limited Androstane 17α-carbonate derivatives for use in the treatment of allergic and inflammatory conditions
CN101248050B (zh) 2005-06-06 2013-07-17 武田药品工业株式会社 有机化合物
WO2007000043A2 (fr) * 2005-06-27 2007-01-04 Ambrilia Biopharma Inc. Dérivés de pyrazolo[3,4-b]pyridin-2-yl]-acide benzoïque en tant qu'inhibiteurs de l'intégrase du vih
WO2007003961A2 (fr) * 2005-06-30 2007-01-11 Prosidion Limited Agonistes de gpcr
US20090325924A1 (en) * 2005-06-30 2009-12-31 Stuart Edward GPCR Agonists
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
WO2007031977A2 (fr) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Inhibiteurs de la phosphodiesterase
ES2363795T3 (es) * 2005-09-29 2011-08-16 Glaxo Group Limited Compuestos de pirazolo[3,4-b]piridina, y su uso como inhibidores de pde4.
TW200730498A (en) 2005-12-20 2007-08-16 Glaxo Group Ltd Compounds
CA2645137A1 (fr) 2006-03-07 2007-09-13 James F. Blake Derives heterobicycliques de pyrazole et methodes d'utilisation
EA200801997A1 (ru) 2006-04-20 2009-04-28 Глаксо Груп Лимитед Новые соединения
JP5440934B2 (ja) 2006-05-24 2014-03-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換プテリジン
MX2008015489A (es) 2006-06-06 2009-01-13 Intra Cellular Therapies Inc Compuestos organicos.
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
CL2007001829A1 (es) 2006-06-23 2008-01-25 Smithkline Beecham Corp P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc.
GB0614570D0 (en) * 2006-07-21 2006-08-30 Glaxo Group Ltd Compounds
PL2046787T3 (pl) 2006-08-01 2011-10-31 Glaxo Group Ltd Związki pirazolo[3,4-b]pirydynowe i ich zastosowanie jako inhibitory PDE4
US8492378B2 (en) 2006-08-03 2013-07-23 Takeda Pharmaceutical Company Limited GSK-3β inhibitor
US9006258B2 (en) 2006-12-05 2015-04-14 Intra-Cellular Therapies, Inc. Method of treating female sexual dysfunction with a PDE1 inhibitor
HRP20120361T1 (hr) 2007-03-14 2012-05-31 Ranbaxy Laboratories Limited DERIVATI PIRAZOLO[3,4-b]PIRIDINA KAO INHIBITORI FOSFODIESTERAZE
WO2008111009A1 (fr) * 2007-03-14 2008-09-18 Ranbaxy Laboratories Limited Dérivés de pyrazolo[3,4-b]pyridine comme inhibiteurs de phosphodiestérases
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
ES2499018T3 (es) 2007-09-20 2014-09-26 Irm Llc Compuestos y composiciones como moduladores de la actividad de GPR119
US8080546B2 (en) 2007-10-26 2011-12-20 Amgen Inc. Pyrazolo-pyridinone derivatives and methods of use
CN101969774A (zh) * 2007-12-06 2011-02-09 细胞内治疗公司 有机化合物
EP2249830A4 (fr) * 2008-02-06 2012-07-18 Glaxo Group Ltd Pharmacophores duals, antagonistes des récepteurs muscariniques et inhibiteurs de l'activité pde4
TW200946526A (en) * 2008-02-06 2009-11-16 Glaxo Group Ltd Dual pharmacophores-PDE4-muscarinic antagonistics
AR070563A1 (es) * 2008-02-06 2010-04-21 Glaxo Group Ltd Compuesto de un biciclo condensado pirazol-piridin-amina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento de enfermedades respiratorias.
WO2009100169A1 (fr) * 2008-02-06 2009-08-13 Glaxo Group Limited Pharmacophores duals, antagonistes des récepteurs muscariniques et inhibiteurs de l'activité pde4
AR070562A1 (es) 2008-02-06 2010-04-21 Glaxo Group Ltd Farmacoforos duales - antagonistas muscarinicos de pde4
EP2100598A1 (fr) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
EP2100599A1 (fr) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
AU2009325091A1 (en) 2008-05-23 2010-06-17 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein inhibitor
US8163743B2 (en) 2008-06-05 2012-04-24 GlaxoGroupLimited 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases
WO2010002209A2 (fr) * 2008-07-02 2010-01-07 Amorepacific Corporation Nouveaux composés, isomère correspondant ou sels pharmaceutiquement acceptables correspondants en tant qu’antagoniste du récepteur vanilloïde et compositions pharmaceutiques les contenant
EP2346867A1 (fr) * 2008-09-19 2011-07-27 Ranbaxy Laboratories Limited Inhibiteurs de phosphodiestérases
EA201170768A1 (ru) 2008-12-06 2012-05-30 Интра-Селлулар Терапиз, Инк. Органические соединения
US8633180B2 (en) 2008-12-06 2014-01-21 Intra-Cellular Therapies, Inc. Organic compounds
MX2011005933A (es) 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
JP5784501B2 (ja) * 2008-12-06 2015-09-24 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
US8859564B2 (en) 2008-12-06 2014-10-14 Intra-Cellular Therapies, Inc. Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione derivatives useful as inhibitors of phosphodiesterase 1
WO2010065153A1 (fr) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Composés organiques
WO2010094643A1 (fr) 2009-02-17 2010-08-26 Glaxo Group Limited Dérivés de quinoline et applications associées dans la rhinite et l'urticaire
CA2747555C (fr) 2009-02-24 2014-04-08 Randall J. Boyle Appareil et procede de traitement des eaux usees
EP2406255B1 (fr) 2009-03-09 2015-04-29 Glaxo Group Limited 4-oxadiazol-2-yl-indazoles en tant qu'inhibiteurs des pi3 kinases
EP2406249A1 (fr) 2009-03-10 2012-01-18 Glaxo Group Limited Dérivés d'indole comme inhibiteurs de ikk2
US20120058984A1 (en) 2009-03-17 2012-03-08 Catherine Mary Alder Pyrimidine derivatives used as itk inhibitors
US20120029054A1 (en) 2009-03-19 2012-02-02 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA)
WO2010107955A2 (fr) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. Inhibition médiée par arn interférence de l'expression génique de btb et de l'homologie cnc 1, facteur de transcription 1 de fermeture éclair de leucine basique (bach 1), utilisant une liste de séquences d'acide nucléique interférant court (ansi)
US20120035247A1 (en) 2009-03-19 2012-02-09 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA)
WO2010107952A2 (fr) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. Inhibition médiée par arn interférence de l'expression génique de facteur de croissance de tissu conjonctif (ctgf) en utilisant un acide nucléique interférant court (ansi)
JP2012521762A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いた神経成長因子β鎖（ＮＧＦβ）遺伝子発現のＲＮＡ干渉媒介性阻害
US20120022142A1 (en) 2009-03-27 2012-01-26 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
EP2411520A2 (fr) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. Inhibition à médiation par l'interférence arn de l'expression du gène de la lymphopoïétine stromale thymique (tslp) faisant appel à de courts acides nucléiques interférents (ansi)
MX2011010072A (es) 2009-03-27 2011-10-06 Merck Sharp & Dohme Inhibicion mediada por interferencia de acido ribonucleico de la expresion del gen de la molecula de adhesion intercelular 1 usando acido nucleico corto de interferencia.
EP2411516A1 (fr) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. Inhibition par interférence arn de l'expression du gène kinase 1 de régulation du signal d'apoptose (ask1) au moyen d'un acide nucléique interférent court (ansi)
JP2012524754A (ja) 2009-04-24 2012-10-18 グラクソ グループ リミテッド Ｃｒａｃチャネル阻害剤としてのピラゾールおよびトリアゾ−ルカルボキサミド
JP2012524755A (ja) 2009-04-24 2012-10-18 グラクソ グループ リミテッド Ｃｒａｃチャネル阻害剤としてのｎ−ピラゾリルカルボキサミド
JP5570589B2 (ja) 2009-04-30 2014-08-13 グラクソ グループ リミテッド Ｐｉ３キナーゼ阻害剤としてのオキサゾール置換インダゾール
WO2010132127A1 (fr) 2009-05-13 2010-11-18 Intra-Cellular Therapies, Inc. Composés organiques
WO2011067366A1 (fr) 2009-12-03 2011-06-09 Glaxo Group Limited Dérivés d'indazole comme inhibiteurs des pi3-kinases
EP2507226A1 (fr) 2009-12-03 2012-10-10 Glaxo Group Limited Nouveaux composés
JP2013512879A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤としてのベンズピラゾール誘導体
WO2011074560A1 (fr) * 2009-12-15 2011-06-23 塩野義製薬株式会社 Dérivé d'oxadiazole ayant une activité d'inhibition de la lipase endothéliale
WO2011107394A1 (fr) 2010-03-01 2011-09-09 Glaxo Group Limited Traitement de troubles de l'anxiété
WO2011110575A1 (fr) 2010-03-11 2011-09-15 Glaxo Group Limited Dérivés de 2-[2-(benzo- ou pyrido-)thiazolylamino]-6- aminopyridine, utiles dans le traitement de maladies respiratoires, allergiques ou inflammatoires
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
TW201209054A (en) 2010-05-28 2012-03-01 Prosidion Ltd Novel compounds
EP2576551A4 (fr) 2010-05-31 2014-04-16 Intra Cellular Therapies Inc Composés organiques
EP2590657A4 (fr) 2010-05-31 2014-02-12 Intra Cellular Therapies Inc Composés organiques
EP2575817A4 (fr) 2010-05-31 2014-01-08 Intra Cellular Therapies Inc Composés organiques
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
US9326987B2 (en) 2010-09-08 2016-05-03 Glaxo Group Limited Indazole derivatives for use in the treatment of influenza virus infection
WO2012032067A1 (fr) 2010-09-08 2012-03-15 Glaxo Group Limited Polymorphes et sels de n-[5-[4-(5-{[(2r,6s-2,6-diméthyl-4-morpholinyl]- méthyl}-1,3-oxazol-2-yl)-1h-indazol-6-yl]-2-(méthyloxy)-3-pyridinyl]- méthanesulfonamide
WO2012035055A1 (fr) 2010-09-17 2012-03-22 Glaxo Group Limited Nouveaux composés
JP2013544794A (ja) 2010-10-21 2013-12-19 グラクソ グループ リミテッド アレルギー性障害、炎症性障害及び免疫障害に作用するピラゾール化合物
EP2630126B1 (fr) 2010-10-21 2015-01-07 Glaxo Group Limited Composés pyrazole agissant contre des états allergiques, immunitaires et inflammatoires
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
EP2683716A1 (fr) 2011-03-11 2014-01-15 Glaxo Group Limited Dérivés pyrido[3,4-b]pyrazine en tant qu'inhibiteurs de syk
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
EP2510928A1 (fr) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium pour l'amélioration du sommeil des patients avec des maldadies respiratoires
WO2012171016A1 (fr) 2011-06-10 2012-12-13 Intra-Cellular Therapies, Inc. Composés organiques
WO2013117693A1 (fr) 2012-02-10 2013-08-15 Glaxosmithkline Intellectual Property Development Limited Inhibiteur de pde4 pour le traitement de la maladie de huntington
MY173949A (en) 2012-04-25 2020-02-28 Takeda Pharmaceuticals Co Nitrogenated heterocyclic compound
JP6205356B2 (ja) 2012-07-13 2017-09-27 武田薬品工業株式会社 複素環化合物
US9801882B2 (en) 2013-02-17 2017-10-31 Intra-Cellular Therapies, Inc. Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases
EP2975031A4 (fr) 2013-03-14 2017-04-19 Takeda Pharmaceutical Company Limited Composé hétérocyclique
EP2968338B1 (fr) 2013-03-15 2019-01-09 Intra-Cellular Therapies, Inc. Inhibiteurs de pde1 utilisés dans le traitement et/ou la prévention de blessures du snc et de maladies, de troubles ou de blessures du snp
PL2970279T3 (pl) 2013-03-15 2021-05-31 Intra-Cellular Therapies, Inc. Związki organiczne
WO2015002230A1 (fr) 2013-07-03 2015-01-08 武田薬品工業株式会社 Composé amide
US10053468B2 (en) 2013-07-03 2018-08-21 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP3026051A4 (fr) 2013-07-24 2017-03-08 Takeda Pharmaceutical Company Limited Composé hétérocyclique
KR20160062178A (ko) 2013-10-17 2016-06-01 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 호흡기 질병의 치료를 위한 ｐｉ３ｋ 억제제
AU2014336250A1 (en) 2013-10-17 2016-04-14 Glaxosmithkline Intellectual Property Development Limited PI3K inhibitor for treatment of respiratory disease
EP3142694A2 (fr) 2014-05-12 2017-03-22 Glaxosmithkline Intellectual Property (No. 2) Limited Compositions pharmaceutiques comprenant danirixin pour traiter des maladies infecteuses
WO2015196186A1 (fr) 2014-06-20 2015-12-23 Intra-Cellular Therapies, Inc. Composés organiques
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
EP3177627B1 (fr) 2014-08-07 2019-07-24 Intra-Cellular Therapies, Inc. Derives de imidazo[1,2-a]-pyrazolo[4,3-e]-pyrimidin-4-one avec activite inhibitrice de la pde1
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
JP6596080B2 (ja) 2014-09-17 2019-10-23 イントラ−セルラー・セラピーズ・インコーポレイテッド 化合物および方法
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
WO2017172795A1 (fr) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Nouvelles compositions et méthodes
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
JP2019524792A (ja) 2016-08-08 2019-09-05 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 化合物
US11291666B2 (en) 2016-09-12 2022-04-05 Intra-Cellular Therapies, Inc. Uses
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
CA3120971A1 (fr) * 2017-11-27 2019-05-31 Dart Neuroscience, Llc Composes furanopyrimidine substitues utilises en tant qu'inhibiteurs de pde1
PL3723807T3 (pl) 2017-12-14 2022-01-24 H. Lundbeck A/S Leczenie skojarzone obejmujące podawanie 1h-pirazolo­[4,3-b]pirydyn
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
US10766893B2 (en) * 2017-12-20 2020-09-08 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
WO2019121840A1 (fr) 2017-12-20 2019-06-27 H. Lundbeck A/S Pyrazolo[3,4-b]pyridines et imidazo[1,5-b]pyridazines utilisées en tant qu'inhibiteurs de pde1
EA202091267A1 (ru) * 2018-01-12 2020-11-03 Ориджен Дискавери Текнолоджис Лимитед 1,2,4-оксадиазольные соединения в качестве ингибиторов сигнальных путей cd47
EP3746081A4 (fr) 2018-01-31 2021-10-27 Intra-Cellular Therapies, Inc. Nouvelles utilisations
US12410175B2 (en) 2019-09-03 2025-09-09 Intra-Cellular Therapies, Inc. Compounds
US12364695B2 (en) 2020-06-02 2025-07-22 Intra-Cellular Therapies, Inc. Methods of treating inflammatory disease
WO2023049199A1 (fr) * 2021-09-24 2023-03-30 Zeno Management, Inc. Composés azole
JPWO2024143336A1 (fr) * 2022-12-28 2024-07-04

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE787249A (fr) 1971-08-05 1973-02-05 Squibb & Sons Inc Derives amino d'acides pyrazolopyridine carboxyliques, leurs esters et les sels de ces composes, ainsi que leurs procedes de preparation
US3833594A (en) * 1971-08-05 1974-09-03 Squibb & Sons Inc Amino derivatives of pyrazolopyridine carboxylic acids and esters
US3856799A (en) * 1971-08-05 1974-12-24 Squibb & Sons Inc Intermediates for production of amino derivatives of pyrazolopyridine carboxylic acids and esters
US3925388A (en) * 1971-08-05 1975-12-09 Squibb & Sons Inc 4-Piperazino-{8 3,4-b{9 pyridine-5-carboxylic acids and esters
CA1003419A (en) 1971-11-23 1977-01-11 Theodor Denzel Process for the production of pyrazolo (3,4-b) pyridines
US3979399A (en) 1972-11-15 1976-09-07 E. R. Squibb & Sons, Inc. Amino derivatives of pyrazolopyridine carboxamides
US3840546A (en) 1972-11-15 1974-10-08 Squibb & Sons Inc Amino derivatives of pyrazolopyridine carboxamides
US3833598A (en) * 1972-12-29 1974-09-03 Squibb & Sons Inc Amino derivatives of pyrazolopyridine-6-carboxylic acids and esters
US4115394A (en) 1974-05-06 1978-09-19 E. R. Squibb & Sons, Inc. Amino derivatives of 6-phenylpyrazolo[3,4-b]pyridines
US4364948A (en) 1981-09-28 1982-12-21 Ici Americas Inc. Pyrazolo[3,4-b]pyridine compounds
GB8425104D0 (en) 1984-10-04 1984-11-07 Ici America Inc Amide derivatives
PL181895B1 (pl) * 1994-06-16 2001-10-31 Pfizer Nowe pirazolo-i pirolopirydyny _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ PL PL PL PL
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
CA2299502A1 (fr) 1997-08-06 1999-02-18 Basf Aktiengesellschaft Amides d'acide tetrazolinonecarboxylique substitues herbicides
US6326379B1 (en) * 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
PL354784A1 (en) 1999-09-30 2004-02-23 Neurogen Corporation Certain alkylene diamine-substituted heterocycles
GB9929685D0 (en) 1999-12-15 2000-02-09 Merck Sharp & Dohme Therapeutic agents
JP2002020386A (ja) 2000-07-07 2002-01-23 Ono Pharmaceut Co Ltd ピラゾロピリジン誘導体
US6670364B2 (en) 2001-01-31 2003-12-30 Telik, Inc. Antagonists of MCP-1 function and methods of use thereof
US7342021B2 (en) 2001-02-08 2008-03-11 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
TWI236474B (en) 2001-04-03 2005-07-21 Telik Inc Antagonists of MCP-1 function and methods of use thereof
FR2828693B1 (fr) 2001-08-14 2004-06-18 Exonhit Therapeutics Sa Nouvelle cible moleculaire de la neurotoxicite
US20050043319A1 (en) * 2001-08-14 2005-02-24 Exonhit Therapeutics Sa Molecular target of neurotoxicity
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
US20060089375A1 (en) 2002-09-16 2006-04-27 Allen David G Pyrazolo[3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors
AU2004299277A1 (en) 2003-12-19 2005-06-30 Glaxo Group Limited Pyrazolo (3,4-b) pyridine compounds, and their use as phosphodiesterase inhibitors
EP1735314A1 (fr) 2004-03-16 2006-12-27 Glaxo Group Limited Compose de pyrazolo [3,4-b]pyridine, et son utilisation en tant qu'inhibiteur de pdea4
GB0405933D0 (en) 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds
GB0405937D0 (en) 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
JP4872068B2 (ja) 2012-02-08
EP1581532B1 (fr) 2010-04-28
AU2003293999A1 (en) 2004-07-14
IL169335A0 (en) 2007-07-04
AU2010202035B9 (en) 2012-09-13
AU2010202035B2 (en) 2012-08-30
IS2795B (is) 2012-08-15
PL392790A1 (pl) 2011-01-03
NO20053600D0 (no) 2005-07-22
TWI354671B (en) 2011-12-21
AR043683A1 (es) 2005-08-10
EP1581532A1 (fr) 2005-10-05
WO2004056823A1 (fr) 2004-07-08
US20060252790A1 (en) 2006-11-09
KR101088848B1 (ko) 2011-12-06
JP2006513258A (ja) 2006-04-20
MXPA05006923A (es) 2005-08-18
PL377880A1 (pl) 2006-02-20
AU2003293999B2 (en) 2010-05-27
CY1110676T1 (el) 2015-06-10
CA2511340A1 (fr) 2004-07-08
NZ540923A (en) 2008-09-26
CO5690642A2 (es) 2006-10-31
CN1751042A (zh) 2006-03-22
ES2345385T3 (es) 2010-09-22
ZA200605901B (en) 2007-12-27
AU2010202035A1 (en) 2010-06-10
NZ570085A (en) 2009-02-28
NO332354B1 (no) 2012-09-03
SI1581532T1 (sl) 2010-08-31
US7528148B2 (en) 2009-05-05
HK1084384A1 (en) 2006-07-28
TW200500364A (en) 2005-01-01
CA2511340C (fr) 2013-02-05
DK1581532T3 (da) 2010-08-16
DE60332396D1 (de) 2010-06-10
BR0317645A (pt) 2005-12-06
IS7913A (is) 2005-06-23
TW201004956A (en) 2010-02-01
GB0230045D0 (en) 2003-01-29
NO20053600L (no) 2005-08-22
CN1751042B (zh) 2011-02-23
KR20050088214A (ko) 2005-09-02
PT1581532E (pt) 2010-07-27
ATE466012T1 (de) 2010-05-15

Similar Documents

Publication Publication Date Title
MA27615A1 (fr) Composes de pyrazolo[3,4-b]pyridine et leur utilisation en tant qu'inhibiteurs de phosphodiesterase
US11358977B2 (en) Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
US12440481B2 (en) Esters and carbamates as modulators of sodium channels
AU2019302534B2 (en) Pyridazine compounds for inhibiting NaV1.8
ATE442367T1 (de) Pyrazolo(3,4-b)pyridinverbindungen und ihre verwendung als phosphodiesterasinhibitoren
EP2951168B1 (fr) Quinoléine et quinoxaline amides comme modulateurs des canaux sodiques
JP6572392B2 (ja) 電位作動型ナトリウムチャネルにおいて選択的活性を有する、ヒドロキシアルキルアミンおよびヒドロキシシクロアルキルアミンで置換されたジアミン−アリールスルホンアミド化合物
US20040087627A1 (en) Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors
CA2422367A1 (fr) Composes de pyrazole pouvant etre utilises comme inhibiteurs de la proteine kinase
JP2019502688A (ja) 電位作動型ナトリウムチャネルにおいて選択的活性を有するジアミノ−アルキルアミノ結合アリールスルホンアミド化合物
US9862678B2 (en) 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death
CA2890692A1 (fr) Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones utilises en tant que suppresseurs de mutation non-sens
GB0128499D0 (en) Therapeutic agents
EP3291810B1 (fr) Inhibiteurs d'histone désacétylase, compositions et méthodes d'utilisation correspondantes
JP2013532121A (ja) チアゾリジンジオン化合物のための新規な合成
ES2610623T3 (es) Nueva síntesis de compuestos de tiazolidindiona
US20050176723A1 (en) (Halo-benzo carbonyl)heterobicyclic p38 kinase inhibiting agents
JP2007508301A5 (fr)
KR20250137706A (ko) Nlrp3 억제제
WO2018122746A1 (fr) Composés d'isoquinoléine, leurs méthodes de préparation et leurs utilisations thérapeutiques dans des maladies associées à l'altération de l'activité de la bêta galactosidase
CA3220896A1 (fr) Inhibiteurs de l'.alpha.-hemolysine de staphylococcus aureus
CN113735825B (zh) 1,2,3,6-四氢吡啶类化合物及其制备方法和用途
EP4496569A1 (fr) Composés sulfonamides cxcr6
CA2722007A1 (fr) Compose cyclique a cinq elements
HK1252487B (en) Histone deacetylase inhibitors and compositions and methods of use thereof